Omnicef Indication:

For the treatment of the respiratory, skin, soft tissue, and ENT infections caused by H. influenzae (including b-lactamase producing strains), H. parainfluenzae (including b-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains), S. pyogenes, S. aureus (including b-lactamase producing strains), and M. catarrhalis.

Omnicef Mechanism Of Action:

As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis by acting on penicillin binding proteins (PBPs).

Omnicef Drug Interactions:

Not Available

Omnicef Food Interactions:

Take without regard to meals.
Avoid taking antacids at same time (up to 2 hours before or after antibiotic).
Avoid taking iron preparations at same time (up to 2 hours before or after antibiotic).

Omnicef Generic Name:


  • CFDN
  • Cefdirnir

Drug Type:

Small Molecule; Approved


Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Absorption is reduced by approximately 15% when administered with a high fat meal.

Toxicity (Overdose):

Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other b-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.

Protein Binding:

60%-70%, binding is independent of concentration.


Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug.

Half Life:

1.7 ± 0.6 hours

Dosage Forms of Omnicef:

Capsule Oral
Powder, for suspension Oral

Chemical IUPAC Name:

(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Organisms Affected:

Enteric gram-negative rods

Omnicef to general, pharmacology

General, pharmacology..